2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Erysipelas: new trials by email Literature Review of Erysipelas trials Research Report on Erysipelas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections Daptomycin, Brilacidin - Skin Infection, Bacterial Infection | Phase 2 | Completed | Cellceutix Corporation | 215 | 2014-02-01 | 2018-09-26 |
| A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study TR701 FA - Major Cutaneous Abscess, Cellulitis | Phase 2 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 200 | 2012-02-15 | 2018-08-29 |
Cellulitis (2) · Abscess (1) · Bacterial Infections (1) · Staphylococcal Infections (1) · Wound Infection (1)
Bacterial Infections and Mycoses (2) · Connective Tissue Diseases (2) · Gram-Positive Bacterial Infections (2) · Infections (2) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Skin Diseases (2) · Skin Diseases, Bacterial (2) · Skin Diseases, Infectious (2) · Skin and Connective Tissue Diseases (2) · Streptococcal Infections (2) · Suppuration (2) · Bacterial Infections (1)
Daptomycin (1) · brilacidin (1) · tedizolid (1)
Cellceutix Corporation (1) · Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
United States (2)
Philippe Prokocimer, MD (1) · William O'Riordan, MD (1)